Rhythm Pharmaceuticals Inc.(RYTM)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

RYTM Rhythm Pharmaceuticals Inc.

休市中 09-11 16:00:00 EDT

104.71

+2.51

+2.46%

盘后104.71

+0.000.00%

19:30 EDT

最高106.57	最低102.25	成交量57.37万
今开102.96	昨收102.20	日振幅4.23%
总市值72.10亿	流通市值68.47亿	总股本6,885万
成交额6,014万	换手率0.88%	流通股本6,539万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"RYTM","market":"US","secType":"STK","nameCN":"Rhythm Pharmaceuticals Inc.","latestPrice":104.71,"timestamp":1789156800000,"preClose":102.2,"halted":0,"volume":573721,"hourTrading":{"tag":"盘后","latestPrice":104.71,"preClose":104.71,"latestTime":"19:30 EDT","volume":19486,"amount":2040377.59,"timestamp":1789169407864,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.024559686888453922,"floatShares":65394076,"shares":68852082,"eps":-3.117162,"marketStatus":"休市中","change":2.51,"latestTime":"09-11 16:00:00 EDT","open":102.96,"high":106.57,"low":102.245,"amount":60142206.283836,"amplitude":0.042319,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.117162,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1789372800000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1507176000000,"exchange":"NASDAQ","adjPreClose":102.2,"preHourTrading":{"tag":"盘前","latestPrice":104,"preClose":102.2,"latestTime":"09:28 EDT","volume":1412,"amount":146062.53264,"timestamp":1789133280217,"change":1.8,"changeRate":0.017613,"amplitude":0.025941},"postHourTrading":{"tag":"盘后","latestPrice":104.71,"preClose":104.71,"latestTime":"19:30 EDT","volume":19486,"amount":2040377.59,"timestamp":1789169407864,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.331219517278582,"impliedVol":0.3808,"impliedVolPercentile":0},"requestUrl":"/m/hq/s/RYTM","defaultTab":"news","newsList":[{"id":"1181502048","title":"德意志银行首次覆盖Rhythm Pharmaceuticals，给予持有评级，目标价120美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1181502048","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1181502048?lang=zh_cn&edition=full","pubTime":"2026-08-28 19:10","pubTimestamp":1787915412,"startTime":"0","endTime":"0","summary":"德意志银行宣布，首次对Rhythm Pharmaceuticals展开覆盖研究。该行给予这家制药公司\"持有\"评级，并将目标股价设定在每股120美元。这一动作，为市场参与者提供了新的分析视角。在生物制药领域，投资机构的态度往往具有风向标意义。Rhythm Pharmaceuticals未来的股价走势，是否会朝着120美元的目标价位靠拢，值得投资者持续关注。德意志银行此次给出的评级，既不悲观亦非强烈看多，反映出一种中性的市场预期。这一决策背后，或许暗含着对该公司现有产品线及在研管线的综合评估。市场对此举的反应，尚待观察。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RYTM","BK4139","BK4588","MEDI","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1184462177","title":"Rhythm Pharmaceuticals宣布Imcivree®（Setmelanotide）在英国获批扩大适应症，用于治疗下丘脑损伤或受损导致的获得性下丘脑肥胖患者的肥胖及饥饿控制","url":"https://stock-news.laohu8.com/highlight/detail?id=1184462177","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1184462177?lang=zh_cn&edition=full","pubTime":"2026-08-11 20:05","pubTimestamp":1786449915,"startTime":"0","endTime":"0","summary":"Rhythm Pharmaceuticals（股票代码：RYTM）今日宣布，其核心药物Imcivree®（Setmelanotide）已获得英国药品监管机构的授权，针对特定患者群体——即因下丘脑损伤或功能受损而罹患获得性下丘脑肥胖的患者——的治疗适应症实现显著扩展。标志着该药物在肥胖及饥饿控制领域的应用迈入新阶段。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4585","RYTM","BK4139","MEDI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1185808167","title":"Rhythm Pharmaceuticals：将与英国国家医疗服务体系紧密合作，敲定Imcivree覆盖指南以应对获得性肥胖症","url":"https://stock-news.laohu8.com/highlight/detail?id=1185808167","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1185808167?lang=zh_cn&edition=full","pubTime":"2026-08-11 20:02","pubTimestamp":1786449769,"startTime":"0","endTime":"0","summary":"Rhythm Pharmaceuticals Inc.宣布，将与英国国家医疗服务体系（NHS）密切协作，共同敲定针对其药物Imcivree的覆盖指南。这一举措旨在为获得性肥胖症患者提供治疗保障。双方的合作将聚焦于如何精准界定覆盖范围，确保患者能够及时获得这一创新疗法。通过细化指南，他们期望能加速药物纳入医保的进程，从而缓解肥胖症带来的公共健康压力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MEDI","BK4585","RYTM","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154959787","title":"Rhythm Pharmaceuticals预估2026年非GAAP运营支出为3.63亿至3.97亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1154959787","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1154959787?lang=zh_cn&edition=full","pubTime":"2026-08-04 19:17","pubTimestamp":1785842229,"startTime":"0","endTime":"0","summary":"Rhythm Pharmaceuticals公司近日发布了财务预估。对于截至2026年12月31日的财年，该公司预计其非GAAP运营支出将在3.63亿美元至3.97亿美元之间。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4588","MEDI","RYTM","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1161176907","title":"异动解读 | 盘前大涨5.58%：Rhythm Pharmaceuticals公布Rm-718二期试验积极数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1161176907","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1161176907?lang=zh_cn&edition=full","pubTime":"2026-08-04 19:11","pubTimestamp":1785841874,"startTime":"0","endTime":"0","summary":"Rhythm Pharmaceuticals Inc. (RYTM) 今日盘前股价大涨5.58%，引发市场关注。消息面上，公司公布了在研药物Rm-718的二期临床试验初步数据，该药物在治疗获得性下丘脑肥胖方面展现出积极的疗效信号，且耐受性良好，常见不良反应为注射部位反应、恶心及呕吐，均属可控范围。这一积极进展为相关治疗领域带来了突破希望，提振了投资者对公司前景的信心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["RYTM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1126936039","title":"Rhythm Pharmaceuticals公布二期试验初步数据：Rm-718在获得性下丘脑肥胖中展现积极疗效信号","url":"https://stock-news.laohu8.com/highlight/detail?id=1126936039","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1126936039?lang=zh_cn&edition=full","pubTime":"2026-08-04 18:56","pubTimestamp":1785840989,"startTime":"0","endTime":"0","summary":"Rhythm Pharmaceuticals Inc.（简称：Rhythm Pharmaceuticals）近日公布了其二期临床试验的初步数据。该试验结果显示，实验性药物Rm-718在治疗获得性下丘脑肥胖方面，成功呈现出了积极的疗效信号。这一发现为相关领域的治疗探索带来了令人鼓舞的进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","RYTM","MEDI","BK4585","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1157936013","title":"Rhythm Pharmaceuticals在研药物Rm-718耐受性良好，常见不良反应为注射部位反应、恶心及呕吐","url":"https://stock-news.laohu8.com/highlight/detail?id=1157936013","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1157936013?lang=zh_cn&edition=full","pubTime":"2026-08-04 18:56","pubTimestamp":1785840974,"startTime":"0","endTime":"0","summary":"Rhythm Pharmaceuticals所研发的候选药物Rm-718，目前展现出令人鼓舞的耐受性特征。在临床应用中，最常被观察到的不良事件集中在注射部位反应、恶心以及呕吐等方面。这些副作用均属于可控范围，且患者整体对该药物的承受能力表现良好，为后续的临床推进提供了积极的支撑。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4588","BK4139","RYTM","MEDI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1156882005","title":"财报前瞻｜Rhythm Pharmaceuticals Inc.本季度营收预计增54.19%，机构多头占优","url":"https://stock-news.laohu8.com/highlight/detail?id=1156882005","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1156882005?lang=zh_cn&edition=full","pubTime":"2026-07-29 00:40","pubTimestamp":1785256854,"startTime":"0","endTime":"0","summary":"Rhythm Pharmaceuticals Inc.将于2026年08月04日发布最新季度财报，市场关注核心产品动能与亏损收窄路径。市场一致预期本季度Rhythm Pharmaceuticals Inc.营收为6,727.69万美元，同比增54.19%；调整后每股收益预计为-0.82美元，同比变动-21.65%。覆盖Rhythm Pharmaceuticals Inc.的机构中，看多观点占主导地位，机构一致认为公司核心产品的销售动能与适应症拓展形成双轮驱动，支撑本季度营收同比增54.19%的市场预期。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"财报前瞻｜Rhythm Pharmaceuticals Inc.本季度营收预计增54.19%，机构多头占优","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RYTM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1170739948","title":"Rhythm Pharmaceuticals宣布《新英格兰医学杂志》发表针对获得性下丘脑肥胖症的3期Transcend试验结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1170739948","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1170739948?lang=zh_cn&edition=full","pubTime":"2026-07-09 05:09","pubTimestamp":1783544956,"startTime":"0","endTime":"0","summary":"Rhythm Pharmaceuticals Inc. 宣布，其针对获得性下丘脑肥胖症的3期Transcend临床试验结果，已获国际顶尖医学期刊《新英格兰医学杂志》发表。研究聚焦于评估公司在研疗法对因下丘脑损伤导致严重肥胖患者群体的疗效与安全性。获得性下丘脑肥胖是一种罕见且严重的疾病，常由脑部肿瘤、手术或创伤对下丘脑造成损伤引发。此次在顶级期刊上公布详细数据，为后续与监管机构的沟通及潜在疗法的推进奠定了坚实的科学基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MEDI","BK4588","BK4585","BK4139","RYTM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1131755559","title":"Rhythm Pharmaceuticals公布多项新数据：展示MC4R激动剂在获得性下丘脑肥胖、Bardet-Biedl综合征及Prader-Willi综合征中的研究成果于ENDO 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=1131755559","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1131755559?lang=zh_cn&edition=full","pubTime":"2026-06-16 04:02","pubTimestamp":1781553736,"startTime":"0","endTime":"0","summary":"Rhythm Pharmaceuticals Inc. 宣布，将在ENDO 2026大会上展示其MC4R激动剂针对获得性下丘脑肥胖、Bardet-Biedl综合征以及Prader-Willi综合征的多项最新研究数据。这些报告将揭示该疗法在多种罕见遗传性肥胖疾病中的最新进展与潜在疗效。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4139","RYTM","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1183006967","title":"Rhythm Pharmaceuticals六个月数据显示Setmelanotide显著改善普瑞德-威利综合征多项指标","url":"https://stock-news.laohu8.com/highlight/detail?id=1183006967","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1183006967?lang=zh_cn&edition=full","pubTime":"2026-06-13 20:03","pubTimestamp":1781352198,"startTime":"0","endTime":"0","summary":"Rhythm Pharmaceuticals Inc. 于2026年5月7日公布的最新六个月临床数据显示，其核心药物Setmelanotide在治疗普瑞德-威利综合征方面展现出积极疗效，显著改善了多项关键临床终点。\n该数据进一步证实了Setmelanotide在控制与PWS相关的严重饥饿感和体重管理方面的潜力。研究结果显示，接受治疗的患者在多个评估维度上均获得了具有统计学意义和临床意义的改善。\n这些积极结果加强了该药物作为PWS患者潜在重要治疗选择的地位，为后续的监管申请和临床开发路径提供了关键支持。公司将持续推进相关研究，以期为这一罕见病患者群体带来新的治疗方案。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","RYTM","BK4585","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1114862762","title":"Rhythm Pharmaceuticals 将公布评估 Setmelanotide 在普瑞德-威利综合征患者中的六个月中期二期试验结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1114862762","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1114862762?lang=zh_cn&edition=full","pubTime":"2026-06-13 04:02","pubTimestamp":1781294534,"startTime":"0","endTime":"0","summary":"Rhythm Pharmaceuticals Inc. 即将公布其药物 Setmelanotide 用于治疗普瑞德-威利综合征患者的二期临床试验中期结果。此次公布的数据将涵盖为期六个月的研究阶段。\n该消息备受市场关注，因 Setmelanotide 的疗效数据可能对公司的未来前景产生重要影响。投资者正密切关注试验结果，以评估该疗法在应对这一罕见遗传性疾病方面的潜力与进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RYTM","BK4139","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143456364","title":"异动解读 | 第一季度营收增长超预期，Rhythm Pharmaceuticals盘中大涨12.79%","url":"https://stock-news.laohu8.com/highlight/detail?id=1143456364","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1143456364?lang=zh_cn&edition=full","pubTime":"2026-05-05 21:52","pubTimestamp":1777989161,"startTime":"0","endTime":"0","summary":"Rhythm Pharmaceuticals (RYTM) 今日盘中股价大幅上涨12.79%，表现强劲。消息面上，公司公布了第一季度财务业绩，显示产品收入达到6010万美元，较去年同期的3270万美元实现显著增长。营收增长主要得益于其针对获得性下丘脑肥胖症的药物IMCIVREE的上市销售。此外，公司第一季度净亏损为5560万美元，基本符合分析师预期。市场对该业绩反应积极。根据LSEG数据，在覆盖该股的16家券商中，有15家给予“买入”或更高评级，目标价中位数为140美元，显示出分析师对公司未来前景的看好。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["RYTM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1177130155","title":"Rhythm Pharmaceuticals宣布Imcivree®（司美兰肽）获欧盟委员会授予上市许可，用于治疗获得性下丘脑性肥胖患者的肥胖及饥饿控制","url":"https://stock-news.laohu8.com/highlight/detail?id=1177130155","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1177130155?lang=zh_cn&edition=full","pubTime":"2026-05-01 18:56","pubTimestamp":1777632976,"startTime":"0","endTime":"0","summary":"Rhythm Pharmaceuticals Inc. (RYTM) 近日宣布，其创新药物Imcivree®（活性成分：司美兰肽）已正式获得欧盟委员会颁发的上市许可。该批准标志着该药物可用于治疗获得性下丘脑性肥胖症患者的肥胖问题及饥饿控制。\n此次授权为患有该罕见疾病的患者提供了新的治疗选择，有望改善其生活质量。公司表示将继续推进相关临床工作，确保药物可及性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RYTM","BK4585","BK4588","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1187320249","title":"财报前瞻｜Rhythm Pharmaceuticals Inc.本季度营收预计增38.35%，机构多头占优","url":"https://stock-news.laohu8.com/highlight/detail?id=1187320249","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1187320249?lang=zh_cn&edition=full","pubTime":"2026-04-28 12:04","pubTimestamp":1777349073,"startTime":"0","endTime":"0","summary":"Rhythm Pharmaceuticals Inc.将于2026年05月05日发布最新季度财报，市场聚焦营收增速与适应症扩展后的放量节奏。市场一致预期本季度Rhythm Pharmaceuticals Inc.营收为5,577.64万，同比增长38.35%；调整后每股收益为-0.85元，同比下降21.52%；公司未披露针对本季度的毛利率与净利润或净利率指引。当前发展前景最大的现有业务为Imcivree在获得“获得性下丘脑性肥胖”适应症后带来的放量潜力，上一季度公司总收入为5,725.30万，同比增长36.87%，为后续扩张提供基数与验证。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"财报前瞻｜Rhythm Pharmaceuticals Inc.本季度营收预计增38.35%，机构多头占优","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RYTM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1165778480","title":"Rhythm Pharmaceuticals获欧盟CHMP积极意见：Imcivree®（Setmelanotide）有望用于治疗下丘脑损伤所致获得性肥胖及饥饿控制","url":"https://stock-news.laohu8.com/highlight/detail?id=1165778480","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1165778480?lang=zh_cn&edition=full","pubTime":"2026-03-26 21:03","pubTimestamp":1774530213,"startTime":"0","endTime":"0","summary":"Rhythm Pharmaceuticals Inc.（RYTM）宣布，其药物Imcivree®（Setmelanotide）获得了欧洲药品管理局人用医药产品委员会（CHMP）的积极评价。该药物拟用于因下丘脑损伤或功能障碍导致的获得性下丘脑肥胖症患者的肥胖治疗及饥饿控制。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RYTM","BK4588","BK4585","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1137824294","title":"FDA批准脑损伤相关肥胖疗法后，Rhythm制药公司盘前股价上涨7.4%","url":"https://stock-news.laohu8.com/highlight/detail?id=1137824294","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1137824294?lang=zh_cn&edition=full","pubTime":"2026-03-20 18:30","pubTimestamp":1774002618,"startTime":"0","endTime":"0","summary":"在获得美国食品药品监督管理局（FDA）对其脑损伤相关肥胖治疗方案的批准后，Rhythm Pharmaceuticals Inc.（RYTM）股价在盘前交易时段强势攀升7.4%。这一监管层面的重大突破，为该公司针对下丘脑肥胖症的治疗产品扫清了上市障碍，显著提振了投资者信心，并直接反映在股价的积极走势上。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4588","BK4139","RYTM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100389039","title":"Rhythm Pharmaceuticals宣布Imcivree®（Setmelanotide）获FDA批准用于治疗获得性下丘脑性肥胖患者","url":"https://stock-news.laohu8.com/highlight/detail?id=1100389039","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1100389039?lang=zh_cn&edition=full","pubTime":"2026-03-20 06:30","pubTimestamp":1773959411,"startTime":"0","endTime":"0","summary":"Rhythm Pharmaceuticals Inc. (RYTM) 近日宣布，其药物Imcivree®（活性成分：Setmelanotide）已获得美国食品药品监督管理局（FDA）的正式批准，适用于治疗获得性下丘脑性肥胖患者。这一重要监管里程碑为患有该罕见代谢疾病的患者提供了新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4139","BK4588","RYTM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1189195604","title":"Rhythm制药高管称2022年启动的试验受GLP-1药物热潮冲击，或致患者脱落率攀升","url":"https://stock-news.laohu8.com/highlight/detail?id=1189195604","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1189195604?lang=zh_cn&edition=full","pubTime":"2026-03-17 05:01","pubTimestamp":1773694879,"startTime":"0","endTime":"0","summary":"Rhythm Pharmaceuticals Inc.（简称Rhythm制药）管理层透露，该公司于2022年启动的临床试验项目遭遇外部环境变化。随着GLP-1类药物在代谢疾病治疗领域迅速崛起，可能对试验进程产生干扰，进而推高了受试者的中途退出比例。\n这一动向折射出创新药研发生态的复杂性与动态性。当同类疗法出现突破性进展时，既存临床试验的推进策略需及时调整，以应对患者偏好变化带来的挑战。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4585","RYTM","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160418964","title":"Rhythm制药高管称：多数安慰剂组患者主动停药，而多数Setmelanotide组患者因副作用中止治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=1160418964","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1160418964?lang=zh_cn&edition=full","pubTime":"2026-03-17 04:50","pubTimestamp":1773694215,"startTime":"0","endTime":"0","summary":"Rhythm Pharmaceuticals Inc.高管披露的最新数据显示，临床试验中服用安慰剂的患者多数是自主选择终止治疗，而接受Setmelanotide药物治疗的患者则主要因不良反应退出研究。\n这一对比凸显了不同治疗路径下的患者决策差异。自主停药往往反映患者对疗效的评估或个人考量，而药物相关中止则指向耐受性问题。Setmelanotide作为针对罕见肥胖症的研究性疗法，其安全性表现正受到密切关注。\n值得注意的是，两组停药动因的差异可能影响对药物有效性的解读。主动停药可能暗示疗效未达预期，而副作用导致的退出则更直接关联药物特性。此类细节对评估实验结果的可靠性具有重要参考价值。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","RYTM","BK4139","BK4585"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.rhythmtx.com","stockEarnings":[{"period":"1week","weight":0.0192},{"period":"1month","weight":-0.1096},{"period":"3month","weight":0.1848},{"period":"6month","weight":0.1983},{"period":"1year","weight":0.0693},{"period":"ytd","weight":-0.0218}],"compareEarnings":[{"period":"1week","weight":-0.0077},{"period":"1month","weight":-0.0106},{"period":"3month","weight":0.0304},{"period":"6month","weight":0.154},{"period":"1year","weight":0.1622},{"period":"ytd","weight":0.1208}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Rhythm Pharmaceuticals, Inc.是一家特拉华州的公司，成立于2013年2月。该公司是一家全球性、商业阶段的生物制药公司，致力于改变患有罕见神经内分泌疾病的患者及其家人的生活。该公司专注于推进黑皮质素-4受体激动剂，包括他们的主要资产IMCIVREE，作为一种精准药物，旨在治疗由罕见的MC4R通路疾病引起的食欲亢进和严重肥胖。","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.051908},{"month":2,"riseRate":0.333333,"avgChangeRate":-0.048958},{"month":3,"riseRate":0.111111,"avgChangeRate":-0.056668},{"month":4,"riseRate":0.555556,"avgChangeRate":0.013671},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.045608},{"month":6,"riseRate":0.555556,"avgChangeRate":0.069919},{"month":7,"riseRate":0.444444,"avgChangeRate":0.238637},{"month":8,"riseRate":0.777778,"avgChangeRate":0.220515},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.037567},{"month":10,"riseRate":0.375,"avgChangeRate":-0.015139},{"month":11,"riseRate":0.777778,"avgChangeRate":0.136999},{"month":12,"riseRate":0.555556,"avgChangeRate":0.041318}],"exchange":"NASDAQ","name":"Rhythm Pharmaceuticals Inc.","nameEN":"Rhythm Pharmaceuticals Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Rhythm Pharmaceuticals Inc.(RYTM)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Rhythm Pharmaceuticals Inc.(RYTM)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Rhythm Pharmaceuticals Inc.,RYTM,Rhythm Pharmaceuticals Inc.股票,Rhythm Pharmaceuticals Inc.股票老虎,Rhythm Pharmaceuticals Inc.股票老虎国际,Rhythm Pharmaceuticals Inc.行情,Rhythm Pharmaceuticals Inc.股票行情,Rhythm Pharmaceuticals Inc.股价,Rhythm Pharmaceuticals Inc.股市,Rhythm Pharmaceuticals Inc.股票价格,Rhythm Pharmaceuticals Inc.股票交易,Rhythm Pharmaceuticals Inc.股票购买,Rhythm Pharmaceuticals Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Rhythm Pharmaceuticals Inc.(RYTM)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Rhythm Pharmaceuticals Inc.(RYTM)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}